Abstract 1580P
Background
Cisplatin nephrotoxicity results from renal accumulation of cisplatin via organic cation transporter 2 (OCT2). Since proton pump inhibitors (PPI) are known to inhibit OCT2 activity, it was thought that the combined use of PPI and cisplatin could prevent nephrotoxicity. In this study, we aimed to evaluate the effect of PPI use on nephrotoxicity in patients with head and neck cancer who received concurrent cisplatin with radiotherapy.
Methods
The data of patients who received cisplatin-assisted radiotherapy as definitive or adjuvant therapy in Gazi University Medical Oncology Clinic were retrospectively analyzed. PPI use, serum creatinine and GFR values were evaluated before and during the treatment. Patients who used PPI for at least 1 week during chemoradiotherapy and had a GFR > 60 before chemoradiotherapy were included in the study. Acute renal failure was determined according to the diagnostic criteria of KDIGO and RIFLE. In order to exclude acute renal failure due to chemoradiotherapy-related oral intake disorder, patients whose creatinine level regressed to basal level within three months after the completion of radiotherapy were not included in the study.
Results
A total of 65 patients were included in the study. The majority of the patients consisted of patients with laryngeal cancer (n=22, 34%) and nasopharyngeal cancer (n=22, 28%). While 35 (54%) of the patients used PPI during chemoradiotherapy, 30 (46%) did not use PPI. Acute renal failure developed in only 4 patients (11%) in patients using PPI, while acute renal failure developed in 10 patients (30%) who did not use PPI (p=0.032).
Conclusions
These findings suggest that co-administration of proton pump inhibitors with cisplatin might prevent cisplatin nephrotoxicity. Currently, there is no agent to prevent platinum nephrotoxicity, and the results of our study seem promising.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.